ADiTx Therapeutics(ADTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADTX ADiTx Therapeutics

盘后交易 03-26 19:01:15 EDT

0.8800

-0.0300

-3.30%

盘后0.8800

+0.00000.00%

18:53 EDT

最高0.9400	最低0.8726	成交量6.77万
今开0.9400	昨收0.9100	日振幅7.41%
总市值45.58万	流通市值19.32万	总股本51.79万
成交额6.11万	换手率30.85%	流通股本21.96万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADTX","market":"US","secType":"STK","nameCN":"ADiTx Therapeutics","latestPrice":0.88,"timestamp":1774555200000,"preClose":0.91,"halted":0,"volume":67725,"hourTrading":{"tag":"盘后","latestPrice":0.88,"preClose":0.88,"latestTime":"18:53 EDT","volume":3196,"amount":2799.99236508,"timestamp":1774565623815,"change":0,"changeRate":0,"amplitude":0.059886},"delay":0,"changeRate":-0.032967032967032996,"floatShares":219558,"shares":517900,"eps":-19410.26,"marketStatus":"盘后交易","change":-0.03,"latestTime":"03-26 19:01:15 EDT","open":0.94,"high":0.94,"low":0.8726,"amount":61115.832382500004,"amplitude":0.074066,"askPrice":0.93,"askSize":892,"bidPrice":0.8048,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-19410.26,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":4,"adr":0,"listingDate":1593489600000,"exchange":"NASDAQ","adjPreClose":0.91,"preHourTrading":{"tag":"盘前","latestPrice":0.9114,"preClose":0.91,"latestTime":"09:26 EDT","volume":495,"amount":448.80969375,"timestamp":1774531611689,"change":0.0014,"changeRate":0.001538,"amplitude":0.043956},"postHourTrading":{"tag":"盘后","latestPrice":0.88,"preClose":0.88,"latestTime":"18:53 EDT","volume":3196,"amount":2799.99236508,"timestamp":1774565623815,"change":0,"changeRate":0,"amplitude":0.059886},"volumeRatio":0.51441,"impliedVol":6.3423,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ADTX","defaultTab":"news","newsList":[{"id":"1189339932","title":"ADiTx Therapeutics收购Ignite Proteomics，破解癌症治疗关键难题：优化疗法选择","url":"https://stock-news.laohu8.com/highlight/detail?id=1189339932","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189339932?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:19","pubTimestamp":1773404375,"startTime":"0","endTime":"0","summary":"ADiTx Therapeutics宣布完成对Ignite Proteomics的战略收购，旨在攻克癌症临床治疗中的核心瓶颈——个体化疗法优选难题。此次并购将通过整合双方在生物标志物检测与蛋白质组学分析领域的技术优势，为肿瘤患者提供更精准的治疗方案决策支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"gpt_icon":0},{"id":"1118817402","title":"ADiTx Therapeutics (纳斯达克: ADTX) 宣布1比8合股 将于2026年3月9日开盘时生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118817402","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118817402?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:33","pubTimestamp":1772717585,"startTime":"0","endTime":"0","summary":"ADiTx Therapeutics (纳斯达克: ADTX) 公布，其1比8的反向股票分割计划已确定于2026年3月9日交易日开盘时正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"gpt_icon":0},{"id":"1122736896","title":"Aditxt发布Bitxbio™增长愿景的最新进展、计划中的数字资产国库、Pearsanta的IPO计划和Evofem的国家上市恢复计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1122736896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122736896?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:01","pubTimestamp":1763470887,"startTime":"0","endTime":"0","summary":"Aditxt发布了关于其Bitxbio™增长愿景的最新进展，包括计划中的数字资产国库、Pearsanta的IPO计划以及Evofem恢复国家上市的计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"gpt_icon":0},{"id":"1162019859","title":"Aditxt, Inc.（纳斯达克：ADTX）宣布于2025年11月3日交易开始时实施1股换113股的反向股拆分","url":"https://stock-news.laohu8.com/highlight/detail?id=1162019859","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162019859?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:32","pubTimestamp":1761769974,"startTime":"0","endTime":"0","summary":"Aditxt, Inc.（纳斯达克：ADTX）宣布于2025年11月3日交易开始时实施1股换113股的反向股拆分。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"gpt_icon":0},{"id":"1194082919","title":"Aditxt子公司Pearsanta启动首个人体研究的招募，研究针对影响全球1.9亿女性的子宫内膜异位症的血液检测，全球市场规模达14.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194082919","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194082919?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:30","pubTimestamp":1761568218,"startTime":"0","endTime":"0","summary":"Aditxt子公司Pearsanta启动首个人体研究的招募，研究针对影响全球1.9亿女性的子宫内膜异位症的血液检测，全球市场规模达14.5亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"gpt_icon":0},{"id":"1133028071","title":"Evofem Biosciences Inc: 向Aditxt发送终止通知，宣布行使终止合并协议的权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1133028071","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133028071?lang=zh_cn&edition=full","pubTime":"2025-10-21 06:00","pubTimestamp":1760997611,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc: 向Aditxt发送终止通知，宣布行使终止合并协议的权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4584","BK4007","ADTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aditxt.com","stockEarnings":[{"period":"1week","weight":-0.3546},{"period":"1month","weight":-0.777},{"period":"3month","weight":-0.9002},{"period":"6month","weight":-0.9988},{"period":"1year","weight":-0.9999},{"period":"ytd","weight":-0.8637}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aditxt, Inc.于2017年9月28日根据特拉华州法律注册成立。该公司是一家临床前阶段的生命科学公司，致力于延长移植患者的生命和提高移植患者的生活质量。他们拥有独家全球许可证，用于将这种基于核酸的技术称为Apoptotic DNA Immunotherapy（ADi），该技术利用新的方法模仿他们的身体自然诱导对自身组织的耐受性。该公司计划开发用于器官移植，植皮和创伤愈合的ADi产品，最初的重点是皮肤移植和其他器官和组织同种异体移植。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.013912},{"month":2,"riseRate":0,"avgChangeRate":-0.246425},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.266429},{"month":4,"riseRate":0.2,"avgChangeRate":-0.266324},{"month":5,"riseRate":0.2,"avgChangeRate":-0.125836},{"month":6,"riseRate":0,"avgChangeRate":-0.251138},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.120854},{"month":8,"riseRate":0.166667,"avgChangeRate":0.274702},{"month":9,"riseRate":0,"avgChangeRate":-0.488285},{"month":10,"riseRate":0,"avgChangeRate":-0.418091},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.288889},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.245759}],"exchange":"NASDAQ","name":"ADiTx Therapeutics","nameEN":"ADiTx Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADiTx Therapeutics(ADTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ADiTx Therapeutics(ADTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ADiTx Therapeutics,ADTX,ADiTx Therapeutics股票,ADiTx Therapeutics股票老虎,ADiTx Therapeutics股票老虎国际,ADiTx Therapeutics行情,ADiTx Therapeutics股票行情,ADiTx Therapeutics股价,ADiTx Therapeutics股市,ADiTx Therapeutics股票价格,ADiTx Therapeutics股票交易,ADiTx Therapeutics股票购买,ADiTx Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADiTx Therapeutics(ADTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ADiTx Therapeutics(ADTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}